Ignyta To Present At The Jefferies 2016 London Healthcare Conference

Ignyta, Inc. (Nasdaq: RXDX),  a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim., M.D., its Chairman and Chief Executive Officer, will make a presentation at the Jefferies 2016 London Healthcare Conference on November 17, 2016, at 4:40 p.m. local time (8:40 a.m. Pacific time) in London, UK.

A webcast of the presentation will be available during the presentation in the Investors section of the company's website at https://www.ignyta.com/investors/, and will be archived and available at that site for 14 days.

About Ignyta, Inc.

Blazing a New Future for Patients with Cancer

At Ignyta, we work tirelessly on behalf of patients with cancer to offer potentially life-saving, precisely targeted therapeutics (Rx) guided by companion diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter uncharted territory, illuminating the molecular drivers of cancer and quickly advancing treatments to address them. This approach embraces even those patients with the rarest cancers, who have the highest unmet need and who may otherwise not have access to effective treatment options. With our pipeline of potentially first-in-class and best-in-class precision medicines, we are pursuing the ultimate goal of not just shrinking tumors, but eradicating cancer relapse and recurrence in precisely defined patient populations.

For more information, please visit:  www.ignyta.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161110005487/en/
Copyright Business Wire 2010

If you liked this article you might like

Loxo Oncology Aims for Genetic Mutation Cancer Drug Approval in 2018

5 Breakout Stocks Under $10 Set to Soar

7 Stocks Under $10 Making Big Moves Toward Big Profits

Loxo Cancer Drug Targets Gene Mutation With Durable Responses in Early Study

5 Stocks Poised for Breakouts